Ultrahuman, an Indian wearable technology company specializing in smart rings for health tracking, has raised $60 million in a Series C funding round led by Qualcomm Ventures. The capital injection will support Ultrahuman’s efforts to grow its business and capture a larger share of the evolving smart wearable market.
- Ultrahuman raised $60 million led by Qualcomm Ventures
- Funding aims to accelerate growth and market expansion
- Software subscriptions now key to profitability
What happened
Ultrahuman, a Bengaluru-based healthtech startup, secured approximately Rs 583 crore (~$60 million) in a Series C funding round led by Qualcomm Ventures. The company issued new preference shares to investors including Qualcomm, Alpha Wave, Labcorp, Blume Ventures, and others to raise capital in two tranches as per regulatory filings.
Launched in 2019, Ultrahuman focuses on developing smart rings that track metrics such as sleep quality and glucose levels. The company reported strong financial performance for the fiscal year ending March 2025, achieving $8.2 million net profit on revenues of $64 million, driven increasingly by its high-margin software subscription services.
Why it matters
The fresh capital infusion positions Ultrahuman to accelerate product development and expand its footprint in the highly competitive wearable technology landscape, especially as other players like Deepinder Goyal's Temple enter the longevity and wellness space. Ultrahuman’s hybrid hardware-to-software business model highlights a shift toward sustainable profitability leveraging recurring subscriber revenue.
However, the company must overcome challenges related to user trust, following a cybersecurity breach earlier in 2026 where unauthorized access to some customer wellness data was reported. How Ultrahuman manages security and data privacy going forward will be critical for maintaining consumer confidence and regulatory compliance.
What to watch next
Market observers will be closely monitoring Ultrahuman’s ability to convert its software subscription offerings, such as Cycle & Ovulation Pro and AFib Detection, into substantial and growing revenue streams. These software products currently represent a smaller but highly profitable segment and are expected to drive the next phase of the company’s growth.
Additionally, Ultrahuman’s expansion strategy within India and potentially international markets will offer insight into the scalability of smart ring technology and its appeal compared to other wearable health devices. Key indicators will include user adoption rates, retention through subscription services, and successful navigation of privacy and security risks.